Michael Kneba
Impact in
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Pathology and Forensic Medicine top 0.01%
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 180
- Chronic Lymphocytic Leukemia Research 176
-
- Lymphoma Diagnosis and Treatment 159
- Co-authors
- Matthias Ritgen (71 shared papers)Monika Brüggemann (40 shared papers)Thorsten Raff (22 shared papers)Michael J. Hallek (62 shared papers)Christiane Pott (38 shared papers)Stephan Stilgenbauer (50 shared papers)Sebastian Böttcher (38 shared papers)Hartmut Doehner (47 shared papers)
- Journals
- Blood (118 papers)Leukemia (36 papers)Nature Communications (14 papers)Haematologica (10 papers)Journal of Clinical Oncology (9 papers)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Michael Kneba
323 papers receiving 35.5k citations
Michael Kneba's Hit Papers
Peers
Comparison fields: 5 of 178
- Genetics 13.1k
- Pathology and Forensic Medicine 13.5k
- Hematology 6.5k
- Cancer Research 5.1k
- Oncology 8.2k
Countries citing papers authored by Michael Kneba
This map shows the geographic impact of Michael Kneba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kneba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kneba more than expected).
Fields of papers citing papers by Michael Kneba
This network shows the impact of papers produced by Michael Kneba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kneba. The network helps show where Michael Kneba may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Kneba, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 336 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 Hit paper breakdown → | 2003 | 2613 |
| 2 | The repertoire of mutational signatures in human cancer Hit paper breakdown → | 2020 | 2339 |
| 3 | Pan-cancer analysis of whole genomes Hit paper breakdown → | 2020 | 2109 |
| 4 | Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial Hit paper breakdown → | 2019 | 1869 |
| 5 | Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Hit paper breakdown → | 2010 | 1557 |
| 6 | Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions Hit paper breakdown → | 2014 | 1221 |
| 7 | Mutations driving CLL and their evolution in progression and relapse Hit paper breakdown → | 2015 | 844 |
| 8 | Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival Hit paper breakdown → | 2011 | 780 |
| 9 | Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial Hit paper breakdown → | 2015 | 709 |
| 10 | ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology Hit paper breakdown → | 2006 | 708 |
| 11 | The evolutionary history of 2,658 cancers Hit paper breakdown → | 2020 | 705 |
| 12 | Patterns of somatic structural variation in human cancer genomes Hit paper breakdown → | 2020 | 550 |
| 13 | First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial Hit paper breakdown → | 2016 | 497 |
| 14 | Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing Hit paper breakdown → | 2020 | 476 |
| 15 | Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial Hit paper breakdown → | 2012 | 466 |
| 16 | 2005 | 453 | |
| 17 | Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial Hit paper breakdown → | 2014 | 436 |
| 18 | Analyses of non-coding somatic drivers in 2,658 cancer whole genomes Hit paper breakdown → | 2020 | 419 |
| 19 | Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies Hit paper breakdown → | 2012 | 416 |
| 20 | Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL Hit paper breakdown → | 2012 | 406 |
About Michael Kneba
Michael Kneba is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Immunology and Oncology, having authored 336 papers that have together received 36.4k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (176 papers), Lymphoma Diagnosis and Treatment (159 papers), Chronic Myeloid Leukemia Treatments (60 papers), Immunodeficiency and Autoimmune Disorders (53 papers), Acute Lymphoblastic Leukemia research (51 papers), Viral-associated cancers and disorders (31 papers), Monoclonal and Polyclonal Antibodies Research (26 papers) and Cancer Genomics and Diagnostics (24 papers). The work is most often cited by research in Genetics (13.1k citations), Pathology and Forensic Medicine (13.5k citations), Hematology (6.5k citations), Cancer Research (5.1k citations) and Oncology (8.2k citations). Michael Kneba has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Matthias Ritgen, Monika Brüggemann, Thorsten Raff, Michael J. Hallek, Christiane Pott, Stephan Stilgenbauer, Sebastian Böttcher, Hartmut Doehner, Nicola Gökbuget and Peter Dreger. Their work appears in journals such as Blood, Leukemia, Nature Communications, Haematologica and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.